Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2001 Apr 2;193(7):785–792. doi: 10.1084/jem.193.7.785

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2001 The Rockefeller University Press

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Anti-T1/ST2 treatment prevents RSV-induced weight loss during immune responses dominated by Th2-driven eosinophilia. Mice were primed with Gvac, Fvac, or β gal-vac and challenged with RSV intranasally 14 d later. Half of each group was given anti-T1/ST2 antibody daily from the day before intranasal RSV challenge (open symbols), whereas the other half was given isotype-matched irrelevant antibody (closed symbols). The percent weight loss or gain on subsequent days was calculated from the original weight of each individual mouse. The mean and standard deviation of five individual mice are shown (A). The data for β gal/RSV mice treated with anti-T1/ST2 is not shown for clarity, but weight loss was not significantly different from control treated β gal/RSV mice. In B, a separate experiment with just G/RSV-infected mice is shown. Each line represents an individual mouse treated with anti-T1/ST2 (dotted line) or irrelevant isotype-matched control (solid line).